Drug intelligence / Profile preview

TX-542

Development stage: Preclinical
Lead developer: EtiraRx
Modality: Small Molecules

Overview

TX-542 is an investigational small molecule drug being developed by EtiraRx for the treatment of estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Currently in the preclinical stage of development, TX-542 is part of EtiraRx's pipeline of small-molecule therapeutics aimed at addressing advanced cancers. While the company's lead compounds, such as ERX-41, are known to target endoplasmic reticulum (ER) stress pathways via lysosomal acid lipase A (LIPA), the specific biological target and mechanism of action for TX-542 have not yet been publicly disclosed. The drug is being positioned to address the significant unmet need in patients with metastatic breast cancer that remains driven by ER signaling or has developed resistance to standard endocrine therapies.

Beyond the preview

Go deeper on TX-542.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TX-542.

Explore the full profile